Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
NCT06687837
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to assess the safety and tolerability of the surgical transplantation of dopaminergic progenitor cells into the brains of participants with Parkinson's disease. The transplanted dopaminergic cells will be derived from the participant's own skin cells.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Parkinson Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 45 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Jeffrey S. Schweitzer, MD, PhD
- Last updated on ClinicalTrials.gov
- March 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.